Utility of creatinine/cystatin C ratio as a predictive marker for adverse effects of chemotherapy in lung cancer: A retrospective study

Objective To determine whether the creatinine/cystatin C (Cr/CysC) ratio, which is influenced by muscle mass, can be used as a predictive marker of the adverse effects of chemotherapy. Methods This single-centre, retrospective, observational study assessed patients with lung cancer. Serum Cr and CysC levels were measured once within 1 month prior the commencement of chemotherapy. Results A total of 25 patients with lung cancer were enrolled in the study: 22 received first-line therapy; three received second-line therapy. A significant difference was noted regarding the Cr/CysC ratios between patients with nonsmall-cell lung cancer (NSCLC) and those with small-cell lung cancer (0.78 versus 0.92, respectively). A significant difference was also noted in the Cr/CysC ratios of patients with NSCLC with toxicity grades <3 and ≥3 (0.84 versus 0.70, respectively). Similar findings were observed in patients with NSCLC who received platinum-based combination therapy (toxicity grade < 3, 0.85; toxicity grade ≥3, 0.69). Conclusion The Cr/CysC ratio could serve as a useful predictive marker for chemotherapy-related adverse effects in patients with NSCLC.

• Publication year

  2015

• Venue

  Journal of International Medical Research

• Publication date

  2015-05-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0300060515579116PMID 26024878
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Precision treatment for cancer: Role of prognostic and predictive markers

  2014cited by this paper
• Creatinine/cystatin C ratio as a surrogate marker of residual muscle mass in amyotrophic lateral sclerosis

  2013influential reference
• Management of Anorexia-Cachexia in Late Stage Lung Cancer Patients.

  2012cited by this paper
• Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score

  2012cited by this paper
• Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma

  2012cited by this paper
• The PCR-invader method (structure-specific 5′ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing

  2011cited by this paper
• Sarcopenia

  2011cited by this paper
• Health-related quality of life and cancer clinical trials

  2011cited by this paper
• Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

  2011cited by this paper
• Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: The Korean Sarcopenic Obesity Study (KSOS) (Diabetes Care (2010) 33, (1497-1499))

  2010cited by this paper
• Prevalence and Determinant Factors of Sarcopenia in Patients With Type 2 Diabetes

  2010cited by this paper
• Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment

  2009influential reference
• A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese Patients

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer

  2009cited by this paper
• Sarcopenic obesity: a new category of obesity in the elderly.

  2008cited by this paper
• Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C.

  2008influential reference
• Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.

  2008influential reference
• Pharmacologic therapy for the cancer anorexia/weight loss syndrome: A data-driven, practical approach.

  2006cited by this paper
• Glomerular filtration rate estimated by cystatin C among different clinical presentations.

  2006cited by this paper
• Cystatin C as a marker of GFR--history, indications, and future research.

  2005cited by this paper
• The Invader assay for SNP genotyping.

  2005cited by this paper
• A sol particle homogeneous immunoassay for measuring serum cystatin C.

  2004cited by this paper
• Invader assay for SNP genotyping.

  2003cited by this paper
• Relationships between body composition parameters and fluorouracil pharmacokinetics.

  2002cited by this paper
• Creatinine Clearance, Cockcroft-Gault Formula and Cystatin C: Estimators of True Glomerular Filtration Rate in the Elderly?

  2002cited by this paper
• Relationship between serum cystatin C and creatinine in kidney and liver transplant patients.

  2002cited by this paper
• From the Chicago MeetingsSarcopenia

  2001cited by this paper
• Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.

  1999cited by this paper
• Involvement of interleukin-6 in activation of lysosomal cathepsin and atrophy of muscle fibers induced by intramuscular injection of turpentine oil in mice.

  1997cited by this paper
• Serum creatinine as an index of renal function: new insights into old concepts.

  1992cited by this paper
• The mechanisms and treatment of weight loss in cancer

  1992cited by this paper
• The Sir David Cuthbertson Medal Lecture 1991. The mechanisms and treatment of weight loss in cancer.

  1992cited by this paper
• Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.

  1991cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins.

  1989cited by this paper
• Influence of Prostaglandins

  1989cited by this paper
• Interleukin-1-induced anorexia in the rat. Influence of prostaglandins.

  1989cited by this paper
• Evaluation of an enzymatic method for determining creatinine in plasma.

  1988cited by this paper
• Difficulties in estimating glomerular filtration rate in the elderly.

  1987cited by this paper
• Assessment of fat-free mass using bioelectrical impedance measurements of the human body.

  1985cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Investigation of CA15-3 and IgE in Iraqi lung cancer patients: A biochemical and immunological analysis

  2025cites this paper
• The diagnostic value of serum Cystatin C in differentiating malignant from benign pulmonary nodules: a retrospective cohort study

  2025cites this paper
• Serum creatinine-to-cystatin C ratio and 1-year mortality risk in advanced breast cancer patients: a multicenter retrospective cohort study

  2025cites this paper
• Sarcopenia index based on serum creatinine and cystatin C is associated with all-cause mortality in patients aged 50 and over with hip fracture.

  2025cites this paper
• Serum Creatinine/Cystatin C Ratio in Chronic Obstructive Pulmonary Disease Patients and its Corelation to Disease Severity

  2024cites this paper
• Lower creatinine-to-cystatin c ratio associated with increased risk of incident amyotrophic lateral sclerosis in the prospective UK biobank cohort

  2024cites this paper
• Serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy

  2024cites this paper
• Sarcopenia index based on serum creatinine and cystatin C is associated with mortality in middle-aged and older adults in Chinese: A retrospective cohort study from the China Health and Retirement Longitudinal Study

  2023cites this paper
• Association between oral frailty and cystatin C-related indices—A questionnaire (OFI-8) study in general internal medicine practice

  2023cites this paper
• Clinical significance of serum cystatin C‐to‐creatinine ratio as a surrogate marker for incident osteoporotic fracture predictions

  2023cites this paper
• Impact of sarcopenia indexes on survival and severe immune acute toxicity in metastatic non-small cell lung cancer patients treated with PD-1 immune checkpoint inhibitors.

  2023cites this paper
• Serum creatinine/cystatin C ratio is a predictor of all-cause mortality for older adults over 80 years

  2023cites this paper
• Energy expenditure profiles and the risk of early limiting toxicity in older patients with cancer: The ELCAPA-25 prospective cohort survey.

  2022cites this paper
• Progress in the Application of Sarcopenia Index in Sarcopenia

  2022cites this paper
• Relationship between the creatinine/cystatin C ratio and muscle mass measured by CT-scan in cancer patients.

  2022cites this paper
• Serum creatinine and cystatin C‐based diagnostic indices for sarcopenia in advanced non‐small cell lung cancer

  2022cites this paper
• Changes in Mortality According to Creatinine/Cystatin C Ratio in Chronic Kidney Disease and Non-chronic Kidney Disease Patients

  2022cites this paper
• Creatinine-to-cystatin C ratio as a marker of skeletal muscle mass for predicting postoperative complications in patients undergoing gastric cancer surgery.

  2021cites this paper
• Serum creatinine to cystatin C ratio is associated with major adverse cardiovascular events in patients with obstructive coronary artery disease.

  2021cites this paper
• The Role of Baseline Sarcopenia Index in Predicting Chemotherapy-Induced Undesirable Effects and Mortality in Older People with Stage III or IV Non-Small Cell Lung Cancer

  2021cites this paper
• Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer

  2021cites this paper
• Serum Creatinine-to-Cystatin-C Ratio as a Potential Muscle Mass Surrogate and Racial Differences in Mortality.

  2021cites this paper
• Serum Creatinine/Cystatin C Ratio Associated with Cross-Sectional Area of Erector Spinae Muscles and Pulmonary Function in Patients with Chronic Obstructive Pulmonary Disease

  2021cites this paper
• COPD_A_339243 3513..3524

  2021cites this paper
• Screening osteoporotic femoral neck without measuring bone mineral density with the use of tartrate resistant acid phosphatase-5b and serum-creatinine-to-cystatin C ratio in Japanese postmenopausal women.

  2020cites this paper
• Creatinine-Cystatin C Ratio and Mortality in Patients Receiving Intensive Care and Continuous Kidney Replacement Therapy: A Retrospective Cohort Study.

  2020cites this paper
• Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease.

  2020cites this paper
• Serum cystatin C level can be an early predictor in community-living people? A clinical question to the conclusion

  2020cites this paper
• Sarcopenia Index as a Predictor of Clinical Outcomes in Older Patients with Coronary Artery Disease

  2020cites this paper
• Association Between Low Muscle Mass and Prognosis of Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

  2020cites this paper
• Creatinine-to-cystatin C ratio and bioelectrical impedance analysis for the assessement of low lean body mass in cancer patients: Comparison to L3-computed tomography scan.

  2020cites this paper
• Assessment of muscle mass in critically ill patients: role of the sarcopenia index and images studies

  2020cites this paper
• The association between cystatin C and COPD: a meta-analysis and systematic review

  2020cites this paper
• Sarcopenia index based on serum creatinine and cystatin C is associated with 3-year mortality in hospitalized older patients

  2020cites this paper
• The impact of shrunken pore syndrome in patient with rheumatic diseases on bone mineral metabolism

  2020cites this paper
• Body composition and sarcopenia: The next‐generation of personalized oncology and pharmacology?

  2019cites this paper
• Validation of the sarcopenia index to assess muscle mass in the critically ill: A novel application of kidney function markers.

  2019cites this paper
• Geriatric assessment of estimated glomerular filtration rate: a cross-sectional study

  2019cites this paper
• Age- and sex-specific reference intervals for the serum cystatin C/creatinine ratio in healthy children (0–18 years old)

  2019cites this paper
• A new diagnostic index for sarcopenia and its association with short‐term postoperative complications in patients undergoing surgery for colorectal cancer

  2019cites this paper
• The value of serum cystatin C in early evaluation of renal insufficiency in patients undergoing chemotherapy: a systematic review and meta-analysis

  2019cites this paper
• The creatinine/cystatin C ratio provides effective evaluation of muscle mass in kidney transplant recipients

  2018cites this paper
• Ratio between estimated glomerular filtration rates of creatinine and cystatin C predicts overall survival in patients with hepatocellular carcinoma

  2018cites this paper
• A sarcopenia index based on serum creatinine and cystatin C cannot accurately detect either low muscle mass or sarcopenia in urban community-dwelling older people

  2018cites this paper
• Relationship between sarcopenia and the serum creatinine/cystatin C ratio in Japanese rural community‐dwelling older adults

  2018cites this paper
• Evaluating Muscle Mass by Using Markers of Kidney Function: Development of the Sarcopenia Index

  2017cites this paper
• CLINICAL USEFULNESS OF CREATININE AND CYSTATIN C- AN UPDATE

  2015cites this paper
• The Journal of Nutrition, Health and Aging

  year unknowncites this paper